MAPT and Alzheimer disease: To date, only our D-peptides have been proven to simultaneously inhibit the aggregation of three pro-aggregant Tau forms (TauFLΔK, TauFL-A152T, TauFL-P301L) found in FTD, AD, PSP, and FTDP-17 diseases (Fig. 5A–C) in a concentration-dependent manner which makes our D-peptides unique and proves their therapeutic potential.